[Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with pegylated interferon alfa-2a and ribavirin]
| Autor: | Maja Ruzic, Vedrana Petrić, Milotka Fabri, Tomislav Preveden, Izabella Fabri, Dajana Lendak |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Thyroid Hormones Cirrhosis Hepatitis C virus lcsh:Medicine Autoimmune hepatitis Hepacivirus medicine.disease_cause Gastroenterology Antiviral Agents Polyethylene Glycols chemistry.chemical_compound Pegylated interferon Rheumatoid Factor Internal medicine Drug Resistance Viral Ribavirin medicine chronic hepatitis C Humans Porphyria cutanea tarda Adverse effect Autoantibodies autoimmune hepatitis business.industry lcsh:R Interferon-alpha General Medicine Hepatitis C Chronic Hirudins Middle Aged medicine.disease Recombinant Proteins chemistry Immunology Drug Therapy Combination Female extrahepatic manifestations Vasculitis business medicine.drug |
| Zdroj: | Srpski Arhiv za Celokupno Lekarstvo, Vol 141, Iss 5-6, Pp 320-324 (2013) |
| ISSN: | 0370-8179 |
| Popis: | Introduction. Thirty to 50% of patients with chronic hepatitis C (CHC) have one or more extrahepatic manifestations (EHMs) of hepatitis C virus (HCV) infection. Objective. The aim of this study was to evaluate the frequency of EHMs and to investigate the efficacy of pegylated interferon (PegIFN)α2a plus ribavirin therapy in patients with HCVrelated EHMs. Methods. The study included 280 patients suffering from CHC and treated with PegIFNα2a and ribavirin. The patients were divided in two groups according to presence or absence of EHMs. We evaluated virological response to antiviral therapy. Results. One or more EHMs were found among 27.9% of patients. Most frequently they had rheumatoid factor in serum (12.5%), organnonspecific antibodies ANA and AGMA (12.4%), thyroid hormone disorders (9.3%), vasculitis (5.7%), diabetes mellitus (4.65%), glomerulonephritis (0.71%), and porphyria cutanea tarda (0.36%). Among the patients with EHMs there was 52.6% of females vs. 30.2% of females in the group of patients without EHMs (p=0.001). HCV genotypes 1 and 4 had 85.9% patients with EHMs vs. 58.4% of patients without EHMs (p=0.000). Progressive fibrosis and cirrhosis were more frequently recorded in the EHM group of patients (32% vs. 23.2%), but without statistically significant difference (p=0.532). Serious adverse events of PegIFNα2a and ribavirin were statistically significantly recorded among the patients with EHMs (46.1% vs. 12.9%; p=0.000). Sustained virological response among the patients with and without EHMs rated 56.9% and 70.8% respectively (p=0.125). Conclusion. Patients with CHC and EHMs treated with combined PegIFNα2a and ribavirin experience handling difficulties, more often have serious adverse events, while successful outcome is achieved in about 50% of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|